Your Cart ( 1 Item )

• A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy
  August 2018 | Volume 17 | Issue 8 | Original Article | 845 | Copyright © August 2018
  Jerry Bagel MD MS, James Zapata, and Elise Nelson LPN CCRC
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs